1. |
|
|
2. |
|
|
3. |
- Fucikova, J, et al.
(author)
-
Calreticulin and cancer
- 2021
-
In: Cell research. - : Springer Science and Business Media LLC. - 1748-7838 .- 1001-0602. ; 31:1, s. 5-16
-
Journal article (peer-reviewed)
|
|
4. |
- Fucikova, J, et al.
(author)
-
Detection of immunogenic cell death and its relevance for cancer therapy
- 2020
-
In: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 11:11, s. 1013-
-
Journal article (peer-reviewed)abstract
- Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer.
|
|
5. |
- Galluzzi, L, et al.
(author)
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- 2020
-
In: Journal for immunotherapy of cancer. - : BMJ. - 2051-1426. ; 8:1
-
Journal article (peer-reviewed)abstract
- Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
|
|
11. |
|
|